Stem cell transplant can be considered a viable treatment option for people with relapsing-remitting multiple sclerosis (MS) who are young, early in the disease course, do not have other major health issues, and have failed to respond to available medications, according to a new set of recommendations. The procedure…

The following multiple sclerosis (MS) news stories caught my eye last week: Stem cell transplant and nerve fiber damage This small study of 43 people with relapsing-remitting multiple sclerosis who underwent autologous hematopoietic stem cell transplant (aHSCT) in Sweden reports that their disability during the period of…

Autologous hematopoietic stem cell transplant (aHSCT) — commonly called stem cell therapy — lessens fatigue and improves quality of life in people with highly active relapsing multiple sclerosis (MS), according to a small study in Lithuania. These gains in the physical and social domains of quality of life…

Stem Cell Transplant Found to Reduce MS Relapses, Ease Disability This is excellent news for those of us who would like to see stem cell transplant for MS become more available and affordable. These researchers analyzed 50 studies covering a total of 4,831 people with MS, ages 26 to…

aHSCT, Stem Cell Therapy for RRMS, Troubled by Unknowns, Paper Says This research team says more studies are needed before aHSCT should be used for people with MS. But this has been the standard response for years to those who have seen benefits with stem cell transplants. Yet there…

Autologous hematopoietic stem cell transplant (aHSCT) has shown some promise as a treatment option for highly active relapsing-remitting multiple sclerosis (RRMS), but more clinical evidence is needed to support its use, a team of researchers in the U.K. suggest. “Uncertainty remains as to how aHSCT compares with current…

Stem Cell Transplant Gaining Ground as MS Therapy Option This comprehensive look at stem cell transplants by Multiple Sclerosis News Today writer Hawken Miller is one of the best overviews of the possible benefits and dangers and the current status of autologous hematopoietic stem cell transplantation (aHSCT) that…

#ACTRIMS2022 – Immune System ‘Reset’ by Stem Cell Transplant At the University of Ottawa, autologous hematopoietic stem cell transplantation (aHSCT) has been used to treat people with aggressive MS since the early 2000s, MS News Today‘s Marisa Wexler reports. This study, which reviewed 71 patients during that period, reports…

Blood Stem Cell Transplant May Help Immune System Longer I’m a proponent of autologous hematopoietic stem cell transplant (aHSCT) to treat MS. The process entails extracting a patient’s own stem cells, usually from the bone marrow, treating them to kill immune cells that trigger MS attacks, and then infusing…

In this installment of our “Expert Voices” series, Multiple Sclerosis News Today asked Tim Coetzee, PhD, some of your questions related to the current state of multiple sclerosis (MS) treatment and cure research. Coetzee serves as the National MS Society’s chief advocacy, services, and science officer. In this capacity, he…

A clinical trial investigating patient-derived stem cell transplants for the treatment of people with severe relapsing forms of multiple sclerosis (MS) has enrolled a patient in Minnesota. The patient was enrolled at the University of Minnesota Medical School, one of two trial sites in the state. An additional 18…

A stem cell transplant can prevent disability progression and maintain disease remission over long periods of time in most patients with relapsing forms of multiple sclerosis (MS) who failed to respond adequately to disease-modifying therapies (DMTs), a study reports. The study, “Long-Term Clinical Outcomes of Hematopoietic…

Autologous hematopoietic stem cell transplant (AHSCT) induces a reduction in relapse rate and physical disability in patients with relapsing-remitting multiple sclerosis (RRMS) who respond inadequately to other treatments, a small study suggests. The study, “Selective cognitive dysfunction and physical disability improvement after autologous hematopoietic stem cell transplantation…

A bone marrow transplant may be particularly useful for those with relapsing forms of multiple sclerosis (MS) who, despite treatment with high-efficacy disease-modifying therapies (DMTs), continue to experience relapses or show signs of new lesions, experts say. According to new recommendations from the National Multiple Sclerosis Society,…

An autologous hematopoietic stem cell transplant (AHSCT) is more effective than Lemtrada (alemtuzumab) at achieving no evidence of disease activity and preventing relapses in people with relapsing-remitting multiple sclerosis (RRMS), a real-life study in Sweden reported. Adverse events (side effects) were more frequent with AHSCT over the first three…

A high-dose chemotherapy combination given to wipe out the immune system before its rescue with autologous hematopoietic stem cell transplant (aHSCT) can cause “transient” damage to neurons and supporting cells of the central nervous system in people with aggressive multiple sclerosis (MS), a Canadian study reports. Nonetheless, its researchers believe…

Many multiple sclerosis (MS) patients consider autologous hematopoietic stem cell transplant (aHSCT) potentially effective in treating their disease, but most report needing more — and more reliable — information to make a reasoned decision regarding its benefits and risks, a survey found. Those who are dissatisfied with their current…

Stem cell therapy, or stem cell transplant, is an emerging yet controversial treatment approach for multiple sclerosis (MS). While some data uphold it as one of the most efficacious MS treatments, to date there have been no controlled studies comparing it to conventional medicines and providing more robust…

Treatment with autologous hematopoietic stem cell transplant (aHSCT) led to a safe and rapid lessening of disability and no clinical relapses in patients with aggressive multiple sclerosis (MS), according to a new study. The research, “The use of autologous hematopoietic stem cell transplantation as a…

Autologous hematopoietic stem cell transplants for relapsing-remitting multiple sclerosis (RRMS) are superior to currently approved disease-modifying drugs, according to a Swedish study published in the Journal of Neurology, Neurosurgery & Psychiatry. In addition, says the review, the procedure’s safety profile has improved in the last decade, and is now just…